Back to Search
Start Over
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
- Source :
-
Antiviral research [Antiviral Res] 2015 May; Vol. 117, pp. 27-38. Date of Electronic Publication: 2015 Feb 23. - Publication Year :
- 2015
-
Abstract
- Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 10,641 viruses collected by WHO-recognized National Influenza Centres between May 2013 and May 2014 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. In addition, neuraminidase (NA) sequence data, available from the WHO CCs and from sequence databases (n=3206), were screened for amino acid substitutions associated with reduced NAI susceptibility. Ninety-five per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 2% (n=172) showed highly reduced inhibition (HRI) against at least one of the four NAIs, commonly oseltamivir, while 0.3% (n=32) showed reduced inhibition (RI). Those showing HRI were A(H1N1)pdm09 with NA H275Y (n=169), A(H3N2) with NA E119V (n=1), B/Victoria-lineage with NA E117G (n=1) and B/Yamagata-lineage with NA H273Y (n=1); amino acid position numbering is A subtype and B type specific. Although approximately 98% of circulating viruses tested during the 2013-2014 period were sensitive to all four NAIs, a large community cluster of A(H1N1)pdm09 viruses with the NA H275Y substitution from patients with no previous exposure to antivirals was detected in Hokkaido, Japan. Significant numbers of A(H1N1)pdm09 NA H275Y viruses were also detected in China and the United States: phylogenetic analyses showed that the Chinese viruses were similar to those from Japan, while the United States viruses clustered separately from those of the Hokkaido outbreak, indicative of multiple resistance-emergence events. Consequently, global surveillance of influenza antiviral susceptibility should be continued from a public health perspective.<br /> (Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Acids, Carbocyclic
Amino Acid Substitution
China epidemiology
Cyclopentanes pharmacology
Disease Outbreaks statistics & numerical data
Drug Resistance, Viral genetics
Europe epidemiology
Guanidines pharmacology
Humans
Influenza A Virus, H1N1 Subtype genetics
Influenza A Virus, H3N2 Subtype genetics
Influenza B virus genetics
Inhibitory Concentration 50
Japan epidemiology
Microbial Sensitivity Tests
Neuraminidase chemistry
Oseltamivir pharmacology
Phylogeny
Pyrans
Sialic Acids
Time Factors
United States epidemiology
World Health Organization
Zanamivir analogs & derivatives
Zanamivir pharmacology
Antiviral Agents pharmacology
Enzyme Inhibitors pharmacology
Influenza A Virus, H1N1 Subtype drug effects
Influenza A Virus, H3N2 Subtype drug effects
Influenza B virus drug effects
Neuraminidase antagonists & inhibitors
Neuraminidase genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1872-9096
- Volume :
- 117
- Database :
- MEDLINE
- Journal :
- Antiviral research
- Publication Type :
- Academic Journal
- Accession number :
- 25721488
- Full Text :
- https://doi.org/10.1016/j.antiviral.2015.02.003